

# The payers' perspective on access to innovation

## HVB AUSTRIA

European & National Medicines Regulatory Systems:  
challenges for an equitable, timely and suitable access  
to innovation

Brussels, 10.5.2017

# Content

- COI
- Innovation – definition
- Perspectives of stakeholders
- Evidence based Medicine and Health Technology assessment
- Pricing and Transparency
- Discussion



## BIOETHICS

AUTONOMY

NON MALEFIZIENZ

BENEFIZIENZ

JUSTICE

AS FOUR DIMENSIONS TO KEEP IN BALANCE

ALSO TO BALANCE PREFERENCES OF INDIVIDUALS WITH  
ENGAGEMENT OF INDIVIDUALS

Bernward Gesang „Eine Verteidigung des Utilitarismus“; Reclam  
Dieter Birnbacher; „Bioethik zZwischen Natur und Interesse“

# COI

I WORK IN THE AUSTRIAN SOCIAL INSURANCE. SO MY POINT OF VIEW IS THE RESPONSIBILITY OF A

- SUSTAINABLE
- APPROPRIATE
- SAFE
- EFFICIENT/EFFECTIV
- ACCESIBLE AND
- ACCEPTABLE

HEALTH CARE SYSTEM FOR ALL CITICENS/INSURED PEOPLE.

THATS THE PERSPECTIVE OF A **PAYER** WITH RESPONSIBILITY AND POLITICAL ACCOUNTABILITY


USUALLY I REFERE TO THE **AUSTRIAN** SYSTEM

AS I AM NOT A NATIVE ENGLISH SPEAKER, PLEASE FORGIVE ERRORS IN GRAMMAR, SPELLING OR UNUSUAL WORDING

ALSO I DID NOT TRANSLATE ALL OLD SLIDES

# Messwerte


## Six Domains of Quality




# Austria a Welfare State based on solidarity



# Innovation - definition



# WILLINGNESS TO PAY



Payers perspective on innovation  
Dr. Gottfried Endel



© HVB-EBM




# Roles and responsibilities

Role	Responsibility
Patients	Health literacy, self awareness, coping, self control...
Provider/Professionals	Professional skills, CME, communication, scientific excellence, transparency (prices)...
Politicians	Framework of the health care system, societys perspective...
Regulators	Market access, infrastrucatur decisions...
<b><u>Payers</u></b>	<b><u>Reimbursement decisions, quality, sustainability...</u></b>
Citicens	Providing sustainable financial basis, societys perspective...
Differents stakeholders	Different objectives
Other political fields	Other political interests
International organizations	International comparisons
.....	.....



# BENEFIT IN KIND



# Pricing and Transparency

- Price as „non disclosure“ clause
- Melphalan for multiple myeloma – essential!
  - „old“ substance
  - no competitor
  - Pricing after GSK sold patents to Aspen Holding + 4.000% (<https://www.thetimes.co.uk/article/drug-giant-s-secret-plan-to-destroy-cancer-medicine-75rg6wt2n> download 9.5.2017)
- adenosine-deaminase-deficient severe combined immunodeficiency (ADA-SCID)
  - Gene therapy : one treatment for the child → promise: cured (no other treatment available; real innovation)
  - Value based pricing discussion: Value of the total life of the child for society (life expectancy in years X yearly contribution of a person to the GDP) : quoted from a coffee discussion at a rare diseases conference

# Discussion

- We want / need innovation
- We deal with uncertainty
  - HTA
- Balance of pricing for services - especially innovations, research and development costs and sustainability of the health care system is a priority.

Thank you for your attention